Indivior (NASDAQ:INDV) Stock Rating Lowered by Zacks Research

Indivior (NASDAQ:INDV) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

INDV has been the subject of a number of other research reports. Weiss Ratings upgraded shares of Indivior from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, June 23rd. Barclays initiated coverage on shares of Indivior in a research note on Thursday, June 18th. They issued an “overweight” rating and a $46.00 target price on the stock. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.29.

Indivior Trading Down 0.6%

Shares of INDV stock opened at $41.03 on Monday. Indivior has a 12 month low of $14.52 and a 12 month high of $42.81. The company has a market capitalization of $5.00 billion, a P/E ratio of 21.04 and a beta of 0.88. The stock has a 50 day moving average of $37.40 and a two-hundred day moving average of $34.75.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. The business had revenue of $317.00 million for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%. Sell-side analysts predict that Indivior will post 4.05 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Ryan Preblick sold 36,000 shares of the business’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $37.70, for a total value of $1,357,200.00. Following the sale, the chief financial officer owned 284,751 shares in the company, valued at approximately $10,735,112.70. The trade was a 11.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.74% of the company’s stock.

Hedge Funds Weigh In On Indivior

Several institutional investors have recently added to or reduced their stakes in the company. Oaktree Capital Management LP grew its stake in Indivior by 2,241.6% during the third quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock worth $6,215,206,000 after buying an additional 246,776,273 shares during the last quarter. Divisadero Street Capital Management LP raised its stake in shares of Indivior by 2,372.5% in the third quarter. Divisadero Street Capital Management LP now owns 3,362,605 shares of the company’s stock valued at $81,072,000 after acquiring an additional 3,226,605 shares during the last quarter. Fuller & Thaler Asset Management Inc. boosted its holdings in shares of Indivior by 101.0% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock worth $228,611,000 after acquiring an additional 3,201,639 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Indivior in the 4th quarter worth approximately $82,687,000. Finally, Vanguard Group Inc. grew its position in Indivior by 57.9% during the 4th quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock worth $196,403,000 after acquiring an additional 2,008,078 shares during the last quarter. 60.33% of the stock is owned by institutional investors.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.